Methotrexate use linked to reduced mortality in RA

Methotrexate use linked to reduced mortality in RA
Use of methotrexate for one year or more is associated with a reduction in the risk of mortality for patients with rheumatoid arthritis, according to a study published online Oct. 8 in Arthritis & Rheumatism.

(HealthDay)—Use of methotrexate for one year or more is associated with a reduction in the risk of mortality for patients with rheumatoid arthritis (RA), according to a study published online Oct. 8 in Arthritis & Rheumatism.

Mary Chester M. Wasko, M.D., from the West Penn Allegheny Health System in Pittsburgh, and colleagues assessed the association between use and mortality in a cohort of 5,626 patients with RA, studied prospectively for 25 years, after controlling for individual propensity scores for methotrexate use.

The researchers found that 666 patients (12 percent) died during follow-up. There was a reduced risk of death with methotrexate use (adjusted hazard ratio, 0.30; 95 percent confidence interval, 0.09 to 1.03). The protective association between methotrexate use and mortality was not accounted for by selective methotrexate cessation immediately before death. The lower risk was only associated with methotrexate use longer than one year, with no stronger associations linked to longer durations of use.

"These findings have implications for the use of MTX in the treatment of RA," the authors write. "For patients in whom MTX monotherapy does not achieve complete control, add-on therapy may be more appropriate than switching to other medications, as MTX may still carry a survival benefit."

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Choice of psoriasis treatment affects CVD event rates

Sep 27, 2012

(HealthDay)—Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined ...

Recommended for you

Cartilage actively contributes to arthritis

Sep 12, 2014

Melbourne researchers have discovered that cartilage plays an active role in the destruction and remodelling of joints seen in rheumatoid arthritis, rather than being an 'innocent bystander' as previously ...

Blocking one receptor could halt rheumatoid arthritis

Sep 10, 2014

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis—and ...

User comments